Overview

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.

Phase:

Phase 3

Details

Lead Sponsor:

UCB Pharma

Treatments:

N 0437
Rotigotine